KCPG
TTPH

Kavar Capital Partners Group’s Tetraphase Pharmaceuticals, Inc. TTPH Stock Holding History

Kavar Capital Partners Group’s Portfolio TTPH Stock Details TTPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-1
Closed – – 554
2015
Q2 		$0 Buy
+1
New +$818 ﹤0.01% 544

Other funds holding TTPH

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return

Kavar Capital Partners Group's TTPH Position: Q3 2015 in Review

Kavar Capital Partners Group sold out of Tetraphase Pharmaceuticals, Inc. (TTPH) in Q3 2015, closing a stake of 1 share.

Kavar Capital Partners Group first reported a position in TTPH in Q2 2015 and held it in 1 quarter. The position peaked at $0 in Q2 2015. 105 funds tracked by Wall St. Rank hold TTPH as of Q3 2015.

  • Kavar Capital Partners Group reported no remaining Tetraphase Pharmaceuticals, Inc. position as of Q3 2015 after selling out during the quarter.
  • Kavar Capital Partners Group sold 1 Tetraphase Pharmaceuticals, Inc. share in Q3 2015.
  • Kavar Capital Partners Group first reported a position in Tetraphase Pharmaceuticals, Inc. in Q2 2015 and held it in 1 quarter.
  • Kavar Capital Partners Group's Tetraphase Pharmaceuticals, Inc. position peaked at $0 in Q2 2015.
  • 105 funds tracked by Wall St. Rank held Tetraphase Pharmaceuticals, Inc. as of Q3 2015.

Based on Kavar Capital Partners Group's 13F filing for Q3 2015, filed 1 May 2019.